Prosecution Insights
Last updated: November 21, 2026
Application No. 18/679,898

PURIFIED EXOSOME PRODUCTS, METHOD OF MAKING, AND METHODS OF USING

Non-Final OA §102§103
Filed
May 31, 2024
Priority
Dec 14, 2017 — provisional 62/598,765 +2 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mayo Foundation for Medical Education and Research
OA Round
3 (Non-Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
1y 8m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1004 resolved
-19.2% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
80 currently pending
Career history
1094
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1004 resolved cases

Office Action

§102 §103
DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of t/e previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/9/2026 has been entered. Status of Application The Examiner acknowledges receipt of the amendments filed on 5/28/2026 wherein claims 63 and 69 have been amended. Claims 63-74 are presented for examination on the merits. The following rejections are made. Response to Applicants’ Arguments Applicant’s arguments filed 5/28/2026 regarding the rejection of claims 63, 64, 69 and 70 made by the Examiner under 35 USC 102(a)(1) over Mitsialis et al. (US 2017/0258840), evidenced by Azevedo et al. (Critical Care, 2007, 11(6), 1-10) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 3/26/2026. Applicant’s arguments filed 5/28/2026 regarding the rejection of claims 63 and 64 made by the Examiner under 35 USC 102(a)(1) over Azevedo et al. (Critical Care, 2007, 11(6), 1-10) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 3/26/2026. Applicant’s arguments filed 5/28/2026 regarding the rejection of claims 63-66 and 69-72 made by the Examiner under 35 USC 103 over Mitsialis et al. (US 2017/0258840), evidenced by Azevedo et al. (Critical Care, 2007, 11(6), 1-10) in view of Imbrie et al. (WO 2013/048734) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 3/26/2026. Applicant’s arguments filed 5/28/2026 regarding the rejection of claims 63, 64, 67-70, 73 amd 74 made by the Examiner under 35 USC 103 over Mitsialis et al. (US 2017/0258840), evidenced by Azevedo et al. (Critical Care, 2007, 11(6), 1-10) in view of Lim (US 2014/0031256) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 3/26/2026. In regards to the 102(a)(1) and 103 rejections over Mitsialis and Azevedo, Applicant asserts the following: Mitsialis fails to teach exosomes prepared by any method other than one that includes tangential flow filtration and/or ultracentrifugation. The recited freeze/thaw process operates on a fundamentally different physical principle and therefore produces a different exosome product because the freeze/thaw process yields an exosome that possesses a lipid bilayer whereas the exosomes produced by tangential flow/centrifugation have a damaged structure. Thus, the exosomes have a different structure as a result of the process. In response to A, Applicant’s argument is not persuasive as it defines a product-by-process limitation which does not appear to provide any distinguishing structural feature. See MPEP 2113. It may be the case that tangential flow/ultracentrifugation results in damage to exosomes but the Examiner is not persuaded that the exosomes purified by the process of Mitsialis are of a different structure than those claimed presently. This is supported by Schroit which states that exosomes isolated by ultracentrifugation produces exosomes having a typical morphology and lipid bilayer (see [0185]). It’s not clear what structural differences, if any, exist for exosomes produced by the prior art and those produced as presently preferred. And so, contrary to Applicant’s assertion, it appears that exosomes produced by the prior art method are no different from exosomes produced by the instantly preferred process. Maintained Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 63, 64, 69 and 70 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mitisialis et al. (US 2017/0258840; of record), evidenced by Azevedo et al. (Critical Care, 2007, 11(6), 1-10). Mitisialis discloses compositions comprising isolated exosomes. The exosomes are to be isolated from blood. It is noted that blood contains platelets (see evidence to Azevedo) and so the isolated exosomes of Mitisialis would necessarily include platelet-derived exosomes. The isolated exosomes are to have a diameter of between 30-100 nm (see [0004]) (e.g. not greater than 300 nm) (see instant claim 64) and may be cryopreserved/lyophilized (i.e. cryodesiccated) so as to enable long-term storage (see [0038, 0091]) (see instant claim 69). It is noted that instant claim 63 requires exosomes be produced by a process which does not include ultracentrifugation or tangential flow filtration. This is a product-by-process limitation per MPEP 2113(I). As the claim does not define how the purified exosomes are different from the exosomes isolated by the prior art, the exosomes will be presumed equivalent absent evidence to the contrary. Claims 63 and 64 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Azevedo et al. (Critical Care, 2007, 11(6), 1-10). Azevedo discloses isolated platelet-derived exosomes which have a diameter of approximately 100 nm (see page 2). Figure 1 indicates that the isolated exosomes are spherical/spheroid. It is noted that instant claim 63 requires exosomes be produced by a process which does not include ultracentrifugation or tangential flow filtration. This is a product-by-process limitation per MPEP 2113(I). As the claim does not define how the purified exosomes are different from the exosomes isolated by the prior art, the exosomes will be presumed equivalent absent evidence to the contrary. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 63-66 and 69-72 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mitisialis et al. (US 2017/0258840; of record), evidenced by/in view of Azevedo et al. (Critical Care, 2007, 11(6), 1-10), in view of Imbrie et al. (WO 2013/048734). Mitisialis and Azevedo are relied upon for disclosure described in the rejection of claim 63, 64, 69 and 70 under 35 U.S.C. 102(a)(1). Mitisialis’ composition can take a variety of forms such as suspensions, injectable formulations, capsules and so on (see [0089-0091]) wherein the composition is to include a variety of formulatory agents such as suspending, stabilizing and/or dispersing agents (see [0091]). Mitisialis fails to teach the composition as comprising a biocompatible matrix comprising collagen, thrombin, gelatin, alginate, or another naturally occurring basement membrane product. Imbrie describes an exosome containing medical formulation. The formulation may be in the form of an oral dosage form, e.g. capsules/tablets, or parenteral dosage forms, e.g. solutions/suspensions (see page 67). Exemplified excipients included in the dosage forms include binders such as alginic acid (alginate) and gelatin (see page 67) (see instant claims 66 and 72). The inclusion of the obvious excipients would necessarily result in a biocompatible matrix. It would have been obvious to modify Mitisialis’ composition to include other known excipients, such as alginate and gelatin, as the said excipients were known to be useful in delivering exosomes for therapeutic benefit. See MPEP 2143(I)(A) which states that combining prior art elements according to known methods to yield predictable results is supportive of obviousness. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claims 63, 64, 67-70, 73 and 74 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mitisialis et al. (US 2017/0258840; of record), evidenced by/in view of Azevedo et al. (Critical Care, 2007, 11(6), 1-10), in view of Lim (US 2014/0031256). Mitisialis and Azevedo are relied upon for disclosure described in the rejection of claim 63, 64, 69 and 70 under 35 U.S.C. 102(a)(1). Mitisialis fails to teach 95% of the exosomes that have a diameter that falls within a distribution range of 100 nm. Lim teaches composition comprising isolated exosomes. Lim teaches that exosomes may be sized by size fractionation and filtration through a membrane with a relevant size cutoff (see [1072]). Exemplified diameter range include between 50 nm to 150 nm (see [0171]) (see instant claim 67). As it was known that the size of the exosomes in the final composition could be selected for by using physical means, e.g. filtration, the selection of a specific particle size distribution from within the broader known range would have been an obvious manipulation of the prior art. Thus, if one of ordinary skill determined that a 95% particle distribution of 100 nm exosomes resulted in a suitable therapeutic outcome, then such a result would have been the product of ordinary skill and common sense rather than of innovation. See MPEP 2144.05(II)(B). Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 4 earlier events
Nov 13, 2025
Examiner Interview (Telephonic)
Nov 14, 2025
Examiner Interview Summary
Dec 17, 2025
Response Filed
Mar 26, 2026
Final Rejection mailed — §102, §103
May 28, 2026
Response after Non-Final Action
Jun 09, 2026
Request for Continued Examination
Jun 10, 2026
Response after Non-Final Action
Nov 12, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799095
N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof
4y 0m to grant Granted Nov 17, 2026
Patent 12797412
PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF
2y 5m to grant Granted Nov 17, 2026
Patent 12788710
CUSTOMIZED COSMETIC COMPOSITIONS, AND METHODS OF REJUVENATING AND UTILIZING CONDITIONED MEDIA AND/OR COMPONENTS THEREOF
4y 1m to grant Granted Nov 10, 2026
Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.8%)
4y 1m (~1y 8m remaining)
Median Time to Grant
High
PTA Risk
Based on 1004 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month